PL4153136T3 - Osmotyczne postacie dawkowania zawierające deutetrabenazynę i sposoby ich stosowania - Google Patents

Osmotyczne postacie dawkowania zawierające deutetrabenazynę i sposoby ich stosowania

Info

Publication number
PL4153136T3
PL4153136T3 PL21737870.2T PL21737870T PL4153136T3 PL 4153136 T3 PL4153136 T3 PL 4153136T3 PL 21737870 T PL21737870 T PL 21737870T PL 4153136 T3 PL4153136 T3 PL 4153136T3
Authority
PL
Poland
Prior art keywords
deutetrabenazine
methods
dosage forms
osmotic dosage
osmotic
Prior art date
Application number
PL21737870.2T
Other languages
English (en)
Inventor
Parag Shah
Mayank Joshi
Soumen PATTANAYEK
Divyang PATEL
Sandeep Pandita
Original Assignee
Auspex Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=78826343&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4153136(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Auspex Pharmaceuticals, Inc. filed Critical Auspex Pharmaceuticals, Inc.
Publication of PL4153136T3 publication Critical patent/PL4153136T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL21737870.2T 2020-06-10 2021-06-10 Osmotyczne postacie dawkowania zawierające deutetrabenazynę i sposoby ich stosowania PL4153136T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063037369P 2020-06-10 2020-06-10
US202063037953P 2020-06-11 2020-06-11
US202063044451P 2020-06-26 2020-06-26
PCT/US2021/036778 WO2021252741A1 (en) 2020-06-10 2021-06-10 Osmotic dosage forms comprising deutetrabenazine and methods of use thereof

Publications (1)

Publication Number Publication Date
PL4153136T3 true PL4153136T3 (pl) 2024-06-24

Family

ID=78826343

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21737870.2T PL4153136T3 (pl) 2020-06-10 2021-06-10 Osmotyczne postacie dawkowania zawierające deutetrabenazynę i sposoby ich stosowania

Country Status (26)

Country Link
US (3) US11311488B2 (pl)
EP (2) EP4364738A3 (pl)
JP (2) JP7419571B2 (pl)
KR (2) KR20240025706A (pl)
CN (1) CN115916154A (pl)
AU (3) AU2021288087B2 (pl)
BR (1) BR112022025185B1 (pl)
CA (1) CA3186425A1 (pl)
CL (1) CL2022003512A1 (pl)
DK (1) DK4153136T3 (pl)
ES (1) ES2975960T3 (pl)
FI (1) FI4153136T3 (pl)
HR (1) HRP20240303T1 (pl)
HU (1) HUE065723T2 (pl)
IL (1) IL298629B2 (pl)
LT (1) LT4153136T (pl)
MX (1) MX2022015742A (pl)
PE (1) PE20230852A1 (pl)
PL (1) PL4153136T3 (pl)
PT (1) PT4153136T (pl)
RS (1) RS65328B1 (pl)
SI (1) SI4153136T1 (pl)
SM (1) SMT202400118T1 (pl)
TW (1) TWI912326B (pl)
WO (1) WO2021252741A1 (pl)
ZA (1) ZA202213478B (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12599598B2 (en) 2020-06-10 2026-04-14 Auspex Pharmaceuticals Llc Osmotic dosage forms comprising deutetrabenazine and methods of use thereof
CN115916154A (zh) 2020-06-10 2023-04-04 奥斯佩克斯医药公司 包括氘代丁苯那嗪的渗透剂型及其使用方法
CN119384270A (zh) * 2022-06-08 2025-01-28 奥斯佩克斯医药公司 包含氘代丁苯那嗪的渗透剂型及其使用方法
WO2025137502A1 (en) * 2023-12-20 2025-06-26 Areteia Therapeutics, Inc. Osmotic tablets of dexpramipexole and methods of manufacturing and use thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
US3546142A (en) 1967-01-19 1970-12-08 Amicon Corp Polyelectrolyte structures
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US5082668A (en) 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US20030161882A1 (en) 2002-02-01 2003-08-28 Waterman Kenneth C. Osmotic delivery system
JP2009507774A (ja) 2005-08-04 2009-02-26 アルザ・コーポレーシヨン 改良された性質を提供するポリマー混合物による半透過性膜を含んでなる浸透性用量形態物
WO2011019956A2 (en) * 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US20120208773A1 (en) * 2008-08-12 2012-08-16 Valeant International (Barbados) Srl Pharmaceutical compositions with tetrabenazine
NZ591615A (en) 2008-09-18 2012-07-27 Auspex Pharmaceuticals Inc Benzoquinoline inhibitors of vesicular monoamine transporter 2
WO2012110912A1 (en) 2011-02-17 2012-08-23 Lupin Limited Sustained release composition of memantine
JP6362601B2 (ja) * 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態
PL3265085T3 (pl) * 2015-03-06 2022-11-07 Auspex Pharmaceuticals, Inc. Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi
US10479787B2 (en) * 2016-04-22 2019-11-19 Lupin Limited Process for preparation of tetrabenazine and deutetrabenazine
US20170312226A1 (en) * 2016-04-28 2017-11-02 Ascent Pharmaceuticals, Inc. Pharmaceutical dosage forms
TWI772382B (zh) * 2017-03-15 2022-08-01 美商奧斯拜客斯製藥有限公司 氘代丁苯那嗪(deutetrabenazine)之類似物、其製備方法及用途
US20190099377A1 (en) * 2017-10-02 2019-04-04 Powder Pharma Coating Inc. Method for dry powder coating osmotic drug delivery system
DK3735228T3 (da) * 2018-03-05 2022-03-14 Amneal Complex Products Res Llc Programmerbar farmaceutiske sammensætninger til krono-lægemiddelfrigivelse
SG11202100303QA (en) * 2018-08-15 2021-02-25 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
CN115916154A (zh) 2020-06-10 2023-04-04 奥斯佩克斯医药公司 包括氘代丁苯那嗪的渗透剂型及其使用方法

Also Published As

Publication number Publication date
HUE065723T2 (hu) 2024-06-28
MX2022015742A (es) 2023-01-19
CA3186425A1 (en) 2021-12-16
JP7419571B2 (ja) 2024-01-22
DK4153136T3 (da) 2024-03-25
US12589075B2 (en) 2026-03-31
EP4364738A2 (en) 2024-05-08
EP4364738A3 (en) 2024-06-19
EP4153136B1 (en) 2024-01-10
CN115916154A (zh) 2023-04-04
US20240307313A1 (en) 2024-09-19
ES2975960T3 (es) 2024-07-18
KR20230016703A (ko) 2023-02-02
WO2021252741A1 (en) 2021-12-16
AU2025205457A1 (en) 2025-07-31
KR102638424B1 (ko) 2024-02-19
JP2023523092A (ja) 2023-06-01
FI4153136T3 (fi) 2024-03-19
NZ795471A (en) 2025-12-19
IL298629A (en) 2023-01-01
AU2023204103B2 (en) 2025-08-14
AU2021288087B2 (en) 2023-03-30
BR112022025185B1 (pt) 2023-10-24
LT4153136T (lt) 2024-03-25
PE20230852A1 (es) 2023-05-29
EP4153136A1 (en) 2023-03-29
CL2022003512A1 (es) 2023-07-28
TW202214246A (zh) 2022-04-16
ZA202213478B (en) 2025-03-26
US11311488B2 (en) 2022-04-26
IL298629B1 (en) 2026-04-01
AU2023204103A1 (en) 2023-07-13
US20230022862A1 (en) 2023-01-26
HRP20240303T1 (hr) 2024-05-10
PT4153136T (pt) 2024-03-22
RS65328B1 (sr) 2024-04-30
IL298629B2 (en) 2026-08-01
TWI912326B (zh) 2026-01-21
US20210386673A1 (en) 2021-12-16
BR112022025185A2 (pt) 2022-12-27
JP7769731B2 (ja) 2025-11-13
SMT202400118T1 (it) 2024-05-14
AU2021288087A1 (en) 2023-01-19
JP2024058686A (ja) 2024-04-26
KR20240025706A (ko) 2024-02-27
SI4153136T1 (sl) 2024-05-31

Similar Documents

Publication Publication Date Title
IL298629B1 (en) Methods and dosage forms for osmotic administration of pharmaceutical preparations containing deuterobenzene
IL281082A (en) Compositions of cxcr4 inhibitors and methods of preparation and use
PT3911648T (pt) 6¿-[[(1s,3s)-3-[[5-(difluorometoxi)-2-pirimidinil]amino]ciclopentil]amino][1(2h),3¿-bipiridina]-2-ona como inibidor de pcsk9 e seus métodos de utilização
IL297625B2 (en) PI3K-alpha inhibitors and methods of using them
IL287973A (en) acss2 inhibitors and methods of their use
IL286248A (en) Tyk2 inhibitors and uses thereof
IL292810A (en) Therapeutic compounds and methods of use
ZA202001487B (en) Liposomal formulations comprising saponin and methods of use
IL279475A (en) Actonucleotidase inhibitors and methods of using them
ZA202400656B (en) 6-aminopyrazolopyrimidine compound and pharmaceutical use thereof
IL312348A (en) HIF-2ALPHA inhibitors and methods of using it
IL264854A (en) Spt5 inhibitors and methods of use thereof
ES3066079T3 (en) Uses of cyp4v2 and rdcvf in preparation of drugs
IL267344A (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
IL313636A (en) Compounds and their use as HDAC6 inhibitors
IL299245A (en) LAIR-1 binding agents and methods of using them
IL311331A (en) Pharmaceutical composition and use thereof
IL267503A (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
GB202306894D0 (en) Therapeutic and prohylactic use of microoganisms
IL291158B2 (en) Iraq inhibitor and its preparation and use
IL305789A (en) USP30 inhibitors and uses thereof
PL3661508T3 (pl) Sposób wytwarzania doustnej postaci dawkowania zawierającej berberynę, doustna postać dawkowania zawierająca berberynę i jej zastosowanie
IL312874A (en) Pharmaceutical composition and use thereof
ES3066151T3 (en) Administration of cebp-beta antagonist and methods of use
ZA201903828B (en) Novel glutaminyl cyclase inhibitors and the use thereof in treatment of various diseases